Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the HER2-Positive Breast Cancer Market Grown from 2024 to 2025?

The market size for HER2-positive breast cancer has seen robust growth in the past few years. It’s predicted to rise from $10.21 billion in 2024 to $10.96 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.34%. The surge during the historical phase can be linked to greater early detection and diagnosis, increased cognizance of HER2-positive subtypes, augmented investments in R&D, expanded adoption of precision medicine, and a heightened emphasis on enhancing patient results.

What Growth Rate Is Anticipated for the HER2-Positive Breast Cancer Market in the Coming Years?

The market size for HER2-positive breast cancer is projected to experience robust growth in the forthcoming years. It is estimated to increase to $14.41 billion by 2029, with a compound annual growth rate (CAGR) of 7.08%. The escalation in this forecasted period can be ascribed to an increased demand for non-invasive monitoring through liquid biopsies, a rising trend towards combination treatments, an augmented focus on immunotherapies and innovative drug formulations, an amplified usage of liquid biopsy methodologies for non-invasive monitoring, and a proliferating count of dedicated cancer treatment facilities. Key trends during this forecast period encompass advancements in targeted therapy, innovative formulations, breakthroughs in immunotherapy strategies, the creation of new HER2-focused therapies, and improvements in biomarkers for effective patient classification.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20832&type=smp

Who Are the Leading Companies in the HER2-Positive Breast Cancer Market?

Major companies operating in the HER2-positive breast cancer market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Co. Ltd., Incyte Corporation, BioNTech SE, MacroGenics Inc., CStone Pharmaceuticals Co. Ltd., Sorrento Therapeutics Inc., Syndax Pharmaceuticals Inc., Fate Therapeutics Inc., Ambrx Biopharma Inc.

What Are the Key Drivers of the HER2-Positive Breast Cancer Market?

The HER2-positive breast cancer market’s growth is anticipated to surge due to the widespread application of immunotherapy. This medical treatment, known as immunotherapy, harnesses or tailors the immune system’s inherent ability to combat diseases such as cancer, infections, and autoimmune conditions. The usage of immunotherapy is lauded for its ability to amplify the immune system’s capacity to detect and eradicate cancer cells, leading to superior effectiveness and fewer side effects compared to traditional treatments. Specifically, in the context of HER2-positive breast cancer, it bolsters the body’s immune response to identify and combat cancer cells that overexpress HER2, thereby ameliorating treatment outcomes and decreasing recurrence risks. To illustrate, the American Association for Cancer Research reported in July 2023 that the FDA had given its approval for 11 immune checkpoint inhibitors (ICIs) by 2023, with at least one ICI approved for treating 20 distinct cancer types and solid tumors that demonstrate specific molecular features. Thus, the robust implementation of immunotherapy is facilitating the growth of the HER2-positive breast cancer market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20832&type=smp

What Are the Key Market Segments in the HER2-Positive Breast Cancer Industry?

The HER2-positive breast cancer market covered in this report is segmented –

1) By Treatment Type: Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types

2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End User

Subsegments:

1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab), Tyrosine Kinase Inhibitors (TKIs), Antibody-Drug Conjugates (ADC), Small Molecule Inhibitors

2) By Chemotherapy: Anthracycline-based Chemotherapy, Taxane-based Chemotherapy, Platinum-based Chemotherapy, Combination Chemotherapy Regimens

3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Antagonists, Estrogen Deprivation Therapy

4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors), Monoclonal Antibodies for Immune Modulation, Cancer Vaccines

5) By Other Treatment Types: Radiation Therapy, Stem Cell Therapy, Hyperthermia Treatment, Gene Therapy, Surgical Interventions (Mastectomy, Breast Conserving Surgery)

What Are the Latest Trends in the HER2-Positive Breast Cancer Market?

Leading businesses within the HER2-positive breast cancer market are striving to develop unique therapies such as HER2-oriented antibody-drug conjugates (ADCs). The intent is to simplify and improve the patient’s treatment experience. HER2-oriented antibody-drug conjugates (ADCs) are specialized cancer treatments that connect an antibody that is specifically designed for HER2 to a cytotoxic drug. This allows the drug to be delivered straight to the HER2-positive cancer cells, enhancing the efficiency of the treatment. In January 2024, for example, Trastuzumab deruxtecan was introduced by AstraZeneca India Pharma Ltd., an Indian biopharmaceutical firm. This cutting-edge therapy, a HER2-oriented antibody-drug conjugate (ADC), was the product of a partnership between AstraZeneca and Daiichi Sankyo. Trastuzumab deruxtecan delivers a cytotoxic drug directly to the HER2-positive cancer cells, allowing for a more focused and successful treatment regimen for patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/her2-positive-breast-cancer-global-market-report

What Are the Key Regional Markets in the HER2-Positive Breast Cancer Industry?

North America was the largest region in the HER2- positive breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-positive breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20832

This Report Delivers Insight On:

1. How big is the her2-positive breast cancer market, and how is it changing globally?

2. Who are the major companies in the her2-positive breast cancer market, and how are they performing?

3. What are the key opportunities and risks in the her2-positive breast cancer market right now?

4. Which products or customer segments are growing the most in the her2-positive breast cancer market?

5. What factors are helping or slowing down the growth of the her2-positive breast cancer market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model